Amgen Under Scrutiny Over Enbrel Marketing
New Jersey's attorney general has launched a probe into whether Amgen Inc. violated patient confidentiality laws by trying to sell its drug Enbrel and marketing the drug for off-label uses....To view the full article, register now.
Already a subscriber? Click here to view full article